drugset / Trial / NCT04007224

Umbilical Cord Blood vs Personalized Treatments for Improving Autistic Disorder

NCT04007224

Phase 1 Completed 35 enrolled Fundatia Bio-Forum Spitalul Angiomedica · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The clinical study evaluates in an open-label, crossover design the comparative efficacy and safety of intranasal oxytocin and autologous umbilical cord blood for improving the functioning of children with autistic spectrum disorder

Timeline

Start
2019-01-17
Primary completion
2023-06-28
Completion
2023-07-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Autologous cord blood Cell therapy Intravenous
Comparator Oxytocin Peptide 5 iu Intranasal
Comparator Oxytocin Peptide 10 iu Intranasal
Comparator Curcumin Small molecule 250 mg Oral
Comparator lecithin Unknown 500 mg
Comparator pironoquinolinquinone Unknown 20 mg